Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-eRADicAte: A Long Term Follow up to eRADicAte (NCT 02097303), an Open Label Phase Two Study of RADium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in CRPC Subjects With Symptomatic Bone Metastasis.

NCT03414437 is registered in ClinicalTrials.gov with Carolina Research Professionals, LLC as lead sponsor.

NCT NCT03414437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-eRADicAte: A Long Term Follow up to eRADicAte (NCT 02097303), an Open Label Phase Two Study of RADium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in CRPC Subjects With Symptomatic Bone Metastasis.
Lead sponsor
Carolina Research Professionals, LLC
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2017
Completion date
October 1, 2021
Enrollment
31 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic